Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2017 | CLARITY: a Phase 2 trial using venetoclax and ibrutinib

Francesco Forconi • 10 Dec 2017
ASH 2017
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax
CLARITY

CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.

More from Francesco Forconi

The VENICE-1 trial: venetoclax monotherapy in R/R CLL 2:08
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
Francesco Forconi • 27 Sep 2024
The structure and function of BCRs in the biology of CLL 2:44
The structure and function of BCRs in the biology of CLL
Francesco Forconi • 27 Sep 2024
The importance of understanding cellular functionality to develop biological therapies for CLL 1:43
The importance of understanding cellular functionality to develop biological therapies for CLL
Francesco Forconi • 27 Sep 2024
Targeting B-cell receptor signaling with BTK degraders to treat CLL 2:21
Targeting B-cell receptor signaling with BTK degraders to treat CLL
Francesco Forconi • 27 Sep 2024

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals